Oclacitinib

DB11441ExperimentalVet approvedSmall molecule

Oclacitinib: Overview.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2, Tyrosine-protein kinase JAK1, and Janus (JAK) kinases
Curator reviewed
Formula / weight: C₁₅H₂₃N₅O₂S · 337.44 g/mol (avg)
Code names: PF-03394197

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyHJWLJNBZVZDLAQ-UHFFFAOYSA-NSMILESCNS(=O)(=O)CC1CCC(CC1)N(C)C1=NC=NC2=C1C=CN2

Targets

What you can answer from here — as of September 13, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oclacitinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.